U.S., March 28 -- ClinicalTrials.gov registry received information related to the study (NCT07495293) titled 'Ultra-hypofractionated Carbon-ion Therapy for Prostate Cancer' on March 16.
Brief Summary: This is a single-arm, exploratory phase I clinical trial evaluating the safety and efficacy of ultra-hypofractionated carbon ion radiotherapy (CIRT) in 6 fractions compared to the conventional 12-fraction regimen in patients with low- and intermediate-risk localized prostate cancer. A total of 20 patients will be enrolled sequentially and treated with CIRT at 7 GyE per fraction, delivered twice weekly on alternating days, for a total of 6 fractions (total prescribed dose: 42 GyE). Androgen deprivation therapy for 6 months will be administered...